{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T22:19:58Z","timestamp":1777501198114,"version":"3.51.4"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.semarthrit.2022.152080","type":"journal-article","created":{"date-parts":[[2022,8,3]],"date-time":"2022-08-03T11:00:13Z","timestamp":1659524413000},"page":"152080","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Cardiovascular safety associated with febuxostat versus allopurinol among patients with gout: Update with accumulated use of febuxostat"],"prefix":"10.1016","volume":"56","author":[{"given":"Anna","family":"Shin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Se Rim","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minji","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"You-Jung","family":"Ha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun Jong","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eun Bong","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9697-1159","authenticated-orcid":false,"given":"Eun Ha","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.semarthrit.2022.152080_bib0001","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1002\/art.40807","article-title":"Contemporary prevalence of gout and hyperuricemia in the United States and decadal trends: The National Health and Nutrition Examination Survey 2007-2016","volume":"71","author":"Chen-Xu","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2022.152080_bib0002","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/s11926-019-0843-8","article-title":"Cardiovascular safety of urate lowering therapies","volume":"21","author":"Kang","year":"2019","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.semarthrit.2022.152080_bib0003","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1056\/NEJMoa1710895","article-title":"Cardiovascular safety of febuxostat or allopurinol in patients with gout","volume":"378","author":"White","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2022.152080_bib0004","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1016\/S0140-6736(20)32234-0","article-title":"Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial","volume":"396","author":"Mackenzie","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.semarthrit.2022.152080_bib0005","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1002\/art.40583","article-title":"New perspectives in rheumatology: implications of the cardiovascular safety of febuxostat and allopurinol in patients with gout and cardiovascular morbidities trial and the associated food and drug administration public safety alert","volume":"70","author":"Choi","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2022.152080_bib0006","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1161\/CIRCULATIONAHA.118.033992","article-title":"Assessment of cardiovascular risk in older patients with gout initiating febuxostat versus allopurinol: population-based cohort study","volume":"138","author":"Zhang","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.semarthrit.2022.152080_bib0007","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1093\/rheumatology\/kez189","article-title":"Comparative cardiovascular risk of allopurinol versus febuxostat in patients with gout: a nation-wide cohort study","volume":"58","author":"Kang","year":"2019","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2022.152080_bib0008","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.020045","article-title":"Updated assessment of cardiovascular risk in older patients with gout initiating febuxostat versus allopurinol","volume":"10","author":"Pawar","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.semarthrit.2022.152080_bib0009","first-page":"799","article-title":"Data resource profile: The National Health Information Database of the National Health Insurance Service in South Korea","volume":"46","author":"Cheol Seong","year":"2017","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.semarthrit.2022.152080_bib0010","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ahj.2004.02.013","article-title":"Accuracy of Medicare claims-based diagnosis of acute myocardial infarction: estimating positive predictive value on the basis of review of hospital records","volume":"148","author":"Kiyota","year":"2004","journal-title":"Am Heart J"},{"issue":"Suppl 1","key":"10.1016\/j.semarthrit.2022.152080_bib0011","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1002\/pds.2312","article-title":"A systematic review of validated methods for identifying cerebrovascular accident or transient ischemic attack using administrative data","volume":"21","author":"Andrade","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"Suppl 1(0 1)","key":"10.1016\/j.semarthrit.2022.152080_bib0012","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/pds.2313","article-title":"A systematic review of validated methods for identifying heart failure using administrative data","volume":"21","author":"Saczynski","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.semarthrit.2022.152080_bib0013","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/j.jclinepi.2004.03.012","article-title":"New ICD-10 version of the Charlson comorbidity index predicted in-hospital mortality","volume":"57","author":"Sundararajan","year":"2004","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.semarthrit.2022.152080_bib0014","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/pst.433","article-title":"Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies","volume":"10","author":"Austin","year":"2011","journal-title":"Pharmaceutical statistics"},{"key":"10.1016\/j.semarthrit.2022.152080_bib0015","series-title":"Survival analysis: a self, learning text","first-page":"131","article-title":"Evaluating the proportional hazards assumption","author":"Kleinbaum","year":"2012"},{"key":"10.1016\/j.semarthrit.2022.152080_bib0016","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1002\/acr.21817","article-title":"Severe cutaneous reactions requiring hospitalization in allopurinol initiators: a population-based cohort study","volume":"65","author":"Kim","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.semarthrit.2022.152080_bib0017","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/annrheumdis-2016-209707","article-title":"2016 updated EULAR evidence-based recommendations for the management of gout","volume":"76","author":"Richette","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2022.152080_bib0018","first-page":"72879","article-title":"2020 American College of Rheumatology guideline for the management of gout","author":"FitzGerald","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2022.152080_bib0019","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1053\/j.ajkd.2018.06.028","article-title":"Febuxostat therapy for patients with stage 3 CKD and asymptomatic hyperuricemia: a randomized trial","volume":"72","author":"Kimura","year":"2018","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.semarthrit.2022.152080_bib0020","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1056\/NEJMoa1915833","article-title":"Effects of allopurinol on the progression of chronic kidney disease","volume":"382","author":"Badve","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2022.152080_bib0021","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1056\/NEJMoa1916624","article-title":"Serum urate lowering with allopurinol and kidney function in type 1 diabetes","volume":"382","author":"Doria","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2022.152080_bib0022","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.semarthrit.2014.05.007","article-title":"Impaired response or insufficient dosage? Examining the potential causes of \u201cinadequate response\u201d to allopurinol in the treatment of gout","volume":"44","author":"Stamp","year":"2014","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2022.152080_bib0023","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1056\/NEJMoa050373","article-title":"Febuxostat compared with allopurinol in patients with hyperuricemia and gout","volume":"353","author":"Becker","year":"2005","journal-title":"N Engl J Med"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017222001317?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017222001317?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T17:12:13Z","timestamp":1758733933000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017222001317"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":23,"alternative-id":["S0049017222001317"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2022.152080","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardiovascular safety associated with febuxostat versus allopurinol among patients with gout: Update with accumulated use of febuxostat","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2022.152080","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"152080"}}